OPKO Health pullback a buying opportunity, says Ladenburg Ladenburg believes new concerns surrounding OPKO Health misconstrue previously released information and do not address prospects for near-term pipeline news. The firm recommends buying the stock following the recent sell-off and reiterates a Buy rating on the name.
News For OPK From The Last 14 Days
Check below for free stories on OPK the last two weeks.
OPKO Health unit gets orphan designation for hemophilia treatment According to a post on the FDA's website, PROLOR Biotech, a unit of OPKO Health, received orphan designation for its long acting recombinant Factor VIIa-CTP3 for the treatment and prophylaxis of bleeding episodes in patietns with hemophilia A or B with inhibitors to factor VIII or factor IX. Reference Link